

According to article 43 paragraph 2 of the Safety and Health at Work Act ("The Official Gazette of RS", number 101/05),

Minister of Labor and Social Policy and Minister of Health pass

## **RULEBOOK**

### **on the preliminary and periodic medical examinations of the employees working at the increased risk work places**

#### **The Rulebook content**

##### **Article 1**

This Rulebook is to determine the manner, procedure and deadlines of the preliminary medical examination of the person taking up employment, that is, the person engaged by the employer to work at an increased risk workplace (hereinafter: the employee) and periodic medical examination of the employee working at an increased risk workplace.

Preliminary and periodic medical examinations are carried out by the work medicine service.

Performing the preliminary and periodic medical examinations procedure, the work medicine service uses the data from the Risk Assessment Act of the employer – concerning risk factors of the increased risk workplace and special health requirements that the employees must meet.

#### **Preliminary medical examination**

##### **Article 2**

The preliminary medical examination is carried out in order to determine and estimate special health requirements, that is, abilities of the employee to work at the increased risk workplace or to use that is to manage particular work equipment – regarding the risk factors stipulated by the Risk Assessment Act with the employer.

The preliminary medical examination of the employee shall be carried out:

- 1) before he has begun to work at the increased risk workplace;
- 2) before the employee has been transferred to the increased risk workplace;
- 3) whenever new risks of the increased risk workplace, the employee works at, are determined;
- 4) provided a new increased risk workplace has been allocated to the employee, who has made a pause in the activities at that workplace for longer than 12 months.

#### **Periodic medical examination**

##### **Article 3**

Periodic medical examination is carried out in order to monitor and estimate health condition, that is, abilities of the employee working at the increased risk workplace or for the use or management of particular work equipment – regarding the risk factors of the mentioned workplace, and within the deadlines prescribed by this Rulebook.

The employer sends the employee to the periodic medical examination:

- 1) not late than 30 days prior to expiration of the deadline stipulated by this Rulebook;
- 2) after the sick-leave, based on a severe injury at work, termination;
- 3) after an illness or an injury unrelated to the work – provided a decreased work ability is suspected of.

### **Medical examinations performance manner**

#### **Article 4**

The preliminary and periodic medical examination of the employee includes:

- 1) general examination – regardless of the the increased risk workplace risk kind and health requirements;
- 2) specific examination – depending on the risk and health requirements the employee working at that workplace must meet.

General and specific examinations are elements of the preliminary and periodic medical examinations of the employee, containing deadlines for periodic medical examinations, which are printed within the annex I and II of this Rulebook, making its constituent part.

The general and specific examination of the employee exposed to the ionizing radiation shall be carried out in the manner, according to the procedure and within the deadlines stipulated by the special regulation.

#### **Article 5**

Provided the work medicine service, estimating the special health requirements of the employee, determines that the preliminary medical documentation is essential for the estimation, it may demand it from the employee's chosen physician.

The employee's chosen physician shall, within three days he has received the demand, submit the medical documentation from paragraph 1 of this article to the work medicine service, and the work medicine service is obliged to return that medical documentation to the employee's chosen physician on the following day.

#### **Article 6**

During the preliminary or periodic medical examination (hereinafter: the medical examination), the work medicine service may use already existing laboratory results – taken within no more than a month at the moment the examination is being performed.

Provided the employer engages another work medicine service, that service may, within eight days from the day it has been engaged, submit an application to the previously engaged work medicine service, asking it to submit the original medical documentation, concerning the performed medical examinations of the employees.

The previously engaged work medicine service shall provide the demanded documentation to the newly engaged work medicine service, within 30 days from the application reception day, as well as keep the submitted medical documentation copy.

### **Medical examination referral**

#### **Article 7**

When sending the employee to the medical examination, the employer fills in the Preliminary Medical Examination Referral – Form 1, that is, the Periodic medical examination Referral – Form 2.

The employer submits two copies of the Form, and one copy is submitted to the work medicine service, while the other copy the employer keeps for himself.

### **Medical examination report**

#### **Article 8**

Report on the preliminary medical examination of the employee – Form 3, that is, the periodic medical examination of the employee – Form 4, is filled in by the work medicine service, in three copies, one of which is submitted to the employer, one to the employee (who submits his copy to the chosen physician), while the remaining one it keeps for its own needs – not later than 15 days from the preliminary, that is, the periodic medical examination.

Reports from paragraph 1 of this article contain the mark that the employee is healthy and able, that is, unable to work at the increased risk workplace, or to use – operate particular work equipment.

#### **Article 9**

The Forms from articles 7 and 8 of this Rulebook have been printed with this Rulebook and they make its constituent part.

### **Notifications**

#### **Article 10**

When the work medicine service, in the preliminary or periodic medical examination procedure, determines health condition disorder of the employee, it shall inform the employee and his chosen physician on the matter, without the delay.

### **Final stipulations**

#### **Article 11**

From the day this Rulebook has come into effect, the Rulebook on the Procedure and Requirements for Performance of the Preliminary and Periodic Medical Examinations of the employees ("The Official Gazette RS", number 23/92) will no longer be valid.

#### **Article 12**

This Rulebook shall come into effect on the eighth day after it has been published in "The Official Gazette of the Republic of Serbia".

Number: 119-01-00002/2007-01  
In Belgrade, November 19, 2007

Minister  
Rasim Ljajić

Minister  
Tomica Milosavljević

**Form 1**

---

(employer)

---

---

(personal identification number from the registry)

---

(address)  
\_\_\_\_\_  
(date)

(activity code)  
\_\_\_\_\_  
(referral number)

**REFERRAL FOR THE PRELIMINARY MEDICAL EXAMINATION  
OF THE EMPLOYEE (E)**

\_\_\_\_\_, born on \_\_\_\_\_, (name, father's name and family name) (personal identification number)  
\_\_\_\_\_ in \_\_\_\_\_, \_\_\_\_\_ by occupation, (birth place and municipality) (occupation name)  
who should perform the job of \_\_\_\_\_, is referred to the PRELIMINARY (workplace name)  
medical examination, so that fulfillment of special health abilities for performance of the  
activities at that work place – which is, by the Risk Assessment Act \_\_\_\_\_ (employer's name, number  
\_\_\_\_\_, determined as an increased risk workplace, could be estimated.  
and date the Act has been passed)

- Brief description of the activities at the work place:

\_\_\_\_\_  
\_\_\_\_\_

- Estimated risks at the workplace and in the work environment – stipulated by the Risk Assessment Act:

\_\_\_\_\_  
(dangers and harmfulness with the measured values)  
\_\_\_\_\_

- Special health requirements stipulated by the Risk Assessment Act – the employee must fulfill:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Employer

(L.S.)

**Form 2**

\_\_\_\_\_  
(employer)  
\_\_\_\_\_  
(address)

\_\_\_\_\_  
(personal identification number from the registry)  
\_\_\_\_\_  
(activity code)

\_\_\_\_\_  
(date)

\_\_\_\_\_  
(referral number)

**REFERRAL FOR THE PERIODIC MEDICAL EXAMINATION OF THE EMPLOYEE**

\_\_\_\_\_, born on \_\_\_\_\_,  
(name, father's name and family name) (personal identification number)  
\_\_\_\_\_ in \_\_\_\_\_, \_\_\_\_\_ by occupation,  
(birth place and municipality) (occupation name)  
who should perform the job of \_\_\_\_\_, is referred to the PERIODIC  
(workplace name)  
medical examination, so that fulfillment of special health abilities for performance of the  
activities at that work place – which is, by the Risk Assessment Act \_\_\_\_\_  
(employer's name, number  
\_\_\_\_\_, determined as an increased risk workplace, could be estimated.  
and date the Act has been passed)

In the preliminary-periodic examination, carried out on \_\_\_\_\_,  
\_\_\_\_\_ (month, day and year)  
in the health institution \_\_\_\_\_ - work medicine service, it has  
(health institution name)  
been determined: \_\_\_\_\_.  
(health condition)

- Brief description of the activities at the work place:

\_\_\_\_\_

- Estimated risks at the workplace and in the work environment – stipulated by the Risk Assessment Act:

\_\_\_\_\_  
(dangers and harmfulness with the measured values)

- Special health requirements stipulated by the Risk Assessment Act – the employee must fulfill:

\_\_\_\_\_  
\_\_\_\_\_

Employer

(L.S.)

**Form 3**

\_\_\_\_\_  
(work medicine service)

\_\_\_\_\_  
(examination date)

\_\_\_\_\_  
(seat)

\_\_\_\_\_  
(outpatient protocol number)

\_\_\_\_\_  
(medical record card number)

**REPORT ON THE PRELIMINARY MEDICAL EXAMINATION OF THE EMPLOYEE**

Based on the referral for the periodic examination number \_\_\_\_\_, from the year \_\_\_\_\_, the examination has been given to

\_\_\_\_\_, born on \_\_\_\_\_,  
(name, father's name and family name) (personal identification number)  
\_\_\_\_\_, \_\_\_\_\_ by occupation, performing the job of  
(occupation name)  
\_\_\_\_\_.  
(workplace name)

Based on the given examinations, in accordance with the Rulebook on Preliminary and Periodic Medical Examinations of the Employees Working at the Increased Risk Workplaces, the following estimation has been made:

**ESTIMATION**

\_\_\_\_\_ is, in regards to health, able-unable to  
(name and family name)  
work at the \_\_\_\_\_ work place, that is, the above named person SHOWS-  
(workplace name)  
DOES NOT SHOW certain pathological conditions, which represent-do not represent the work  
adverse effect.

\_\_\_\_\_  
(place)  
\_\_\_\_\_  
(date)

Estimated by  
\_\_\_\_\_  
(name and family name of the work medicine expert)

(L.S.)

**Form 4**

\_\_\_\_\_  
(work medicine service)  
\_\_\_\_\_  
(seat)

\_\_\_\_\_  
(examination date)  
\_\_\_\_\_  
(outpatient protocol number)  
\_\_\_\_\_

(medical record card number)

**REPORT ON THE PERIODIC MEDICAL EXAMINATION OF THE EMPLOYEE**

Based on the referral for the periodic examination number \_\_\_\_\_, from the year \_\_\_\_\_, the examination has been given to

\_\_\_\_\_, born on \_\_\_\_\_, (name, father's name and family name) (personal identification number) \_\_\_\_\_, by occupation, performing the job of \_\_\_\_\_ (occupation name) \_\_\_\_\_ (workplace name).

Based on the given examinations, in accordance with the Rulebook on Preliminary and Periodic Medical Examinations of the Employees Working at the Increased Risk Workplaces, the following estimation has been made:

**ESTIMATION**

\_\_\_\_\_ is, in regards to health, able-unable to (name and family name) work at the \_\_\_\_\_ work place, that is, the above named person SHOWS- (workplace name) DOES NOT SHOW certain pathological conditions, which represent-do not represent the work adverse effect.

\_\_\_\_\_  
(place)  
\_\_\_\_\_  
(date)

Estimated by \_\_\_\_\_  
(name and family name of the work medicine expert)

(L.S.)

**Annex 1**

**General part of the preliminary and periodic examinations of the employees working at the increased risk workplaces program**

**A preliminary examination includes:**



- 1) Anamnestic data (work anamnesis, major problems, current disease, personal anamnesis, family anamnesis, social epidemiology data);
- 2) Medical examination with the basic anthropometry (body weight, body height, calculation of body mass index (BMI));
- 3) Basic laboratory analyses:
  - (1) of blood (erythrocyte sedimentation rate, number of leukocytes, erythrocytes, hematocrit, glucose concentration)
  - (2) urine (presence of proteins, sugars, bilirubins, urobilinogen and urine sediment);
- 4) Vision function examination: sharpness of near- and distance-vision, deep vision;
- 5) Tonal liminar Audiometry;
- 6) Spirometrics with the volume flow curve;
- 7) Electrocardiogram (12 leads);
- 8) Filling in questionnaires on the previous diseases, habits, allergies;
- 9) Thorax radiography (PA) – when the doctor decides;
- 10) Specific examinations and/or examinations depending on the determined harmfulness and danger, that is, special health requirements for performance of specific activities at the workplace, in accordance with the Risk Assessment Act.

**Periodic examination includes:**

- 1) Anamnestic data (work anamnesis, major problems, current disease, personal anamnesis, family anamnesis, social epidemiology data);
- 2) Medical examination with the basic anthropometry (body weight, body height, calculation of body mass index (BMI));
- 3) Basic laboratory analyses:
  - (1) of blood (erythrocyte sedimentation rate, number of leukocytes, erythrocytes, hematocrit, glucose concentration)
  - (2) urine (presence of proteins, sugars, bilirubins, urobilinogen and urine sediment);
- 4) Electrocardiogram (12 leads);
- 5) Spirometrics with the volume flow curve;
- 6) Thorax radiography (PA) – when the doctor decides;
- 7) Specific examinations and/or examinations depending on the determined harmfulness and danger, that is, special health requirements for performance of specific activities at the workplace, in accordance with the Risk Assessment Act.

## Annex II

### Specific part of the program of preliminary and periodic examinations of the employees working at the increased risk workplaces

	PRELIMINARY EXAMINATION	PERIODIC EXAMINATION	Time int. in the month
1	2	3	4
<b>1.0.</b>	<b>REQUIREMENTS AND STRAINS</b>	<b>REQUIREMENTS AND STRAINS</b>	
1.1.	<b>VISAGE</b>	<b>VISAGE</b>	12
	Targeted anamnesis. Functions testing: foria, fusion, color eyesight. The preserved field of sight requirement: perimetry. The preserved night vision requirement: dark adaptation examination.	Targeted anamnesis. Functions testing: sharpness of near- and distance-vision, deep vision, foria, fusion, color eyesight. The preserved field of sight requirement: perimetry. The preserved night vision requirement: dark adaptation examination.	
1.2.	<b>SMELL AND TASTE</b>	<b>SMELL AND TASTE</b>	24
	Targeted anamnesis with the smell and taste examination (testing).	Targeted anamnesis with the smell and taste examination (testing).	
1.3.	<b>BALANCE</b>	<b>BALANCE</b>	12
	Targeted anamnesis. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Vision functions testing: foria, fusion, color eyesight.	Targeted anamnesis. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Vision functions testing: sharpness of near- and distance-vision, deep vision, foria, fusion, color eyesight.	
1.4.	<b>HEARING</b>	<b>HEARING</b>	12
	Targeted anamnesis.	Targeted anamnesis. Tonal liminar Audiometry	
1.5.	<b>MEDIUM HARD AND HARD DYNAMIC PHYSICAL WORK (=&gt;4 MET)</b>	<b>MEDIUM HARD AND HARD DYNAMIC PHYSICAL WORK (=&gt;4 MET)</b>	12

	Targeted anamnesis. The Harvard Step test with ECG, pulse and blood pressure record making before and after the test.	Targeted anamnesis. The Harvard Step test with ECG, pulse and blood pressure record making before and after the test.	
1.6.	<b>STATISTIC PHYSICAL WORK</b>	<b>STATISTIC PHYSICAL WORK</b>	12
	Targeted anamnesis. The muscle groups engaged in statistical work strength examination	Targeted anamnesis. The muscle groups engaged in statistical work strength examination	
1.7.	<b>REPEATED ABRUPT MOVEMENTS AND FORCED POSITIONS</b>	<b>REPEATED ABRUPT MOVEMENTS AND FORCED POSITIONS</b>	12
	Targeted anamnesis. Bone and muscular difficulties and disturbances questionnaire.	Targeted anamnesis. Bone and muscular difficulties and disturbances questionnaire.	
1.8.	<b>PSYCHOLOGICAL REQUIREMENTS AND STRAINS (COGNITIVE, PSYCHOSENSORY AND PSYCHOMOTORICAL)</b>	<b>PSYCHOLOGICAL REQUIREMENTS AND STRAINS (COGNITIVE, PSYCHOSENSORY AND PSYCHOMOTORICAL)</b>	12
	Targeted anamnesis. Psychological examination (examination of psycho-physiological abilities, cognitive functions and personality characteristics).	Targeted anamnesis. Psychological examination (examination of psycho-physiological abilities, cognitive functions and personality characteristics).	
<b>2.0.</b>	<b>PHYSICAL HARMFULNESS</b>	<b>PHYSICAL HARMFULNESS</b>	
2.1.	<b>IMPROPER LIGHTING</b>	<b>IMPROPER LIGHTING</b>	24
	Targeted anamnesis. Vision functions testing: foria, fusion, color eyesight. Perimetry. Dark adaptation examination.	Targeted anamnesis. Vision functions testing: sharpness of near- and distance-vision, deep vision, foria, fusion, color eyesight. Perimetry. Dark adaptation examination.	
2.2.	<b>UNFAVORABLE MICROCLIMATIC CONDITIONS WORK</b>	<b>UNFAVORABLE MICROCLIMATIC CONDITIONS WORK</b>	12

	<p>Targeted anamnesis. The Harvard Step test with ECG, pulse and blood pressure record making before and after the test. *Dynamic skin thermometric (Cold test).</p>	<p>Targeted anamnesis. The Harvard Step test with ECG, pulse and blood pressure record making before and after the test. *Dynamic skin thermometric (Cold test).</p>	
<b>Note: *For the persons exposed to low temperatures.</b>			
2.3.	<b>NOISE</b>	<b>NOISE</b>	12
	<p>Targeted anamnesis. Noise at work questionnaire. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Counseling on hearing preservation preventive measures and instructions for use of personal protection means (equipment).</p>	<p>Targeted anamnesis. Tonal liminar Audiometry. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Counseling on hearing preservation preventive measures and instructions for use of personal protection means (equipment).</p>	
2.4.	<b>GENERAL VIBRATIONS</b>	<b>GENERAL VIBRATIONS</b>	12
	<p>Targeted anamnesis. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk).</p>	<p>Targeted anamnesis. Tonal liminar Audiometry. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk).</p>	
2.5.	<b>LOCAL VIBRATIONS</b>	<b>ЛОКАЛНЕ ВИБРАЦИЈЕ</b>	12
	<p>Targeted anamnesis. Vibration at work questionnaire. Dynamic skin thermometric (Cold test). Pain, touch and vibration sensitivity examination. Phalen's test.</p>	<p>Targeted anamnesis. Vibration at work questionnaire. Dynamic skin thermometric (Cold test). Pain, touch and vibration sensitivity examination. Phalen's test. Allen's test. Dynamometry.</p>	

2.6.			12
2.7.	<b>NON-IONIZING RADIATION</b>	<b>NON-IONIZING RADIATION</b>	12
	Targeted anamnesis. Ophthalmological examination (optical media examination with dilated pupils).	Targeted anamnesis. Vision functions testing: sharpness of near- and distance-vision, deep vision. Ophthalmological examination (optical media examination with dilated pupils).	
2.8.	<b>HEIGHTENED OR LOWERED AIR PRESSURE</b>	<b>HEIGHTENED OR LOWERED AIR PRESSURE</b>	12
	Targeted anamnesis. Respiratory questionnaire. Vision functions testing: foria, fusion, color eyesight. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Psychological examination (examination of psycho-physiological abilities and personality characteristics). The Harvard Step test with ECG, pulse and blood pressure record making before and after the test.	Targeted anamnesis. Respiratory questionnaire. Vision functions testing: sharpness of near- and distance-vision, deep vision, foria, fusion, color eyesight. Tonal liminar Audiometry. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Psychological examination (examination of psycho-physiological abilities and personality characteristics). The Harvard Step test with ECG, pulse and blood pressure record making before and after the test.	
			12

2.9.	<b>ACCELERATION CHANGES (ACCELERATION OR DECELERATION)</b>	<b>ACCELERATION CHANGES (ACCELERATION OR DECELERATION)</b>	
	<p>Targeted anamnesis.  Vision functions testing: foria, fusion, color eyesight.  Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk).  Psychological examination (examination of psycho-physiological abilities and personality characteristics).  The Harvard Step test with ECG, pulse and blood pressure record making before and after the test.</p>	<p>Targeted anamnesis.  Vision functions testing: sharpness of near- and distance-vision, deep vision, foria, fusion, color eyesight.  Tonal liminar Audiometry.  Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk).  Psychological examination (examination of psycho-physiological abilities and personality characteristics).  The Harvard Step test with ECG, pulse and blood pressure record making before and after the test.</p>	

<b>3.0.</b>	<b>CHEMICAL HARMFULNESS</b>	<b>CHEMICAL HARMFULNESS</b>	
3.1.	<i>METALS AND NON-METALS</i>	<i>METALS AND NON-METALS</i>	
3.1.1.	<b>ALUMINIUM</b>	<b>ALUMINIUM</b>	12
	Targeted anamnesis. Respiratory diseases questionnaire. Chest X-Ray (PA).	Targeted anamnesis. Respiratory diseases questionnaire. Chest X-Ray (PA). Biological monitoring (at the end of a five-working-day week): urine concentration of aluminium expressed per gram creatinine.	
<b>Note: chest X-ray every 5 years.</b>			
3.1.2.	<b>ANTIMONY AND ITS COMPOUNDS</b>	<b>ANTIMONY AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase and $\gamma$ -glutamyl transpeptidasa in blood. Chest X-Ray (PA).	Targeted anamnesis. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase and $\gamma$ -glutamyl transpeptidasa in blood. Chest X-Ray (PA).	
<b>Note: chest X-ray every three years after the five-year exposure.</b>			
3.1.3.	<b>ARSENIC AND ITS COMPOUNDS</b>	<b>ARSENIC AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Respiratory questionnaire. Detailed examination of upper respiratory tract mucous membrane, skin and nails. Pain, touch and temperature sensitivity examination of arms and legs. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood. Determination of urine concentration of albumins, $\beta$ 2-microglobulin (expressed per gram creatinine) and/or $\alpha$ 1-microglobulin (expressed per gram creatinine).	Targeted anamnesis. Respiratory questionnaire. Detailed examination of upper respiratory tract mucous membrane, skin and nails. Pain, touch and temperature sensitivity examination of arms and legs. Determination of reticulocyte number, (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood. Determination of urine concentration of albumins, $\beta$ 2-microglobulin (expressed per gram creatinine) and/or $\alpha$ 1-microglobulin (expressed per gram creatinine).	

	Chest X-Ray (PA).	Chest X-Ray (PA). Biological monitoring (at the end of a five-working-day week): urine concentration of the total inorganic arsenic expressed per gram creatinine and blood concentration of methemoglobin.	
	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
3.1.4.	<b>COPPER AND ITS COMPOUNDS</b>	<b>COPPER AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT). Urine concentration of copper, expressed per gram creatinine, and blood concentration of copper.	Targeted anamnesis. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT). Biological monitoring (at the end of a five-working-day week): urine concentration of copper, expressed per gram creatinine, and blood concentration of copper.	
3.1.5.	<b>BERILIUM AND ITS COMPOUNDS</b>	<b>BERILIUM AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Specific allergy questionnaire. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood. Chest X-Ray (PA).	Targeted anamnesis. Specific allergy questionnaire. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood. Chest X-Ray (PA).	
	<b>Note: chest X-ray every 5 years.</b>		
3.1.6.	<b>ZINC AND ITS COMPOUNDS</b>	<b>ZINC AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire.	Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Biological monitoring (at the end of a five-working-day week): urine concentration of zinc, expressed per gram creatinine, and blood concentration of zinc.	
3.1.7.	<b>PHOSPHORUS AND ITS COMPOUNDS</b>	<b>PHOSPHORUS AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Respiratory questionnaire.	Targeted anamnesis. Respiratory questionnaire.	



	Detailed examination of upper respiratory tract mucous membrane, oral cavity, jaw and skin.	Detailed examination of upper respiratory tract mucous membrane, oral cavity, jaw and skin.	
	Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, Ca, P, urea and creatinine in blood.	Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, Ca, P, urea and creatinine in blood. Lower jaw X-ray.	
	<b>Note: lower jaw X-ray every 5 years after the ten-year exposure.</b>		
3.1.8.	<b>CHROME AND ITS COMPOUNDS</b>	<b>CHROME AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), urea and creatinine in blood. Determination of urine concentration of albumins, $\beta$ 2-microglobulin (expressed per gram creatinine) and/or $\alpha$ 1-microglobulin (expressed per gram creatinine). Smell examination. Chest X-Ray (PA).	Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), urea and creatinine in blood. Determination of urine concentration of albumins, $\beta$ 2-microglobulin (expressed per gram creatinine) and/or $\alpha$ 1-microglobulin (expressed per gram creatinine). Smell examination. Chest X-Ray (PA). Biological monitoring (at the end of a five-working-day week): urine concentration of zinc, expressed per gram creatinine.	
	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
3.1.9.	<b>CADMIUM AND ITS COMPOUNDS</b>	<b>CADMIUM AND ITS COMPOUNDS</b>	12

	<p>Targeted anamnesis. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood. Determination of urine concentration of albumins, <math>\beta</math>2-microglobulin (expressed per gram creatinine) and/or <math>\alpha</math>1-microglobulin (expressed per gram creatinine). Smell examination. Chest X-Ray (PA).</p>	<p>Targeted anamnesis. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood. Determination of urine concentration of albumins, <math>\beta</math>2-microglobulin (expressed per gram creatinine) and/or <math>\alpha</math>1-microglobulin (expressed per gram creatinine). Smell examination. Chest X-Ray (PA). Pelvis and femora X-rays. Biological monitoring (at the end of a five-working-day week): urine concentration of cadmium, expressed per gram creatinine, and blood concentration of cadmium.</p>	
	<b>Note: chest X-ray every three years after the five-year exposure. Pelvis and femora X-rays every five years after the five-year exposure</b>		
3.1.10.	<b>TIN AND ITS INORGANIC COMPOUNDS</b>	<b>TIN AND ITS INORGANIC COMPOUNDS</b>	12
	<p>Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).</p>	<p>Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).</p>	
	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
3.1.11.	<b>ORGANIC COMPOUNDS OF TIN</b>	<b>ORGANIC COMPOUNDS OF TIN</b>	12
	<p>Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase and <math>\gamma</math>-glutamyl transpeptidasa in blood. Chest X-Ray (PA).</p>	<p>Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase and <math>\gamma</math>-glutamyl transpeptidasa in blood. Chest X-Ray (PA).</p>	
	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
3.1.12.	<b>COBALT AND ITS COMPOUNDS</b>	<b>COBALT AND ITS COMPOUNDS</b>	12

	<p>Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Chest X-Ray (PA).</p>	<p>Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Smell examination. Chest X-Ray (PA). Biological monitoring (at the end of a five-working-day week): urine concentration of cobalt, expressed per gram creatinine, and blood concentration of cobalt.</p>	
<b>Note: chest X-ray every three years after the five-year exposure. Biological monitoring starting from 2010.</b>			
3.1.13.	<b>MAGNESIUM AND ITS COMPOUNDS</b>	<b>MAGNESIUM AND ITS COMPOUNDS</b>	12
	<p>Targeted anamnesis. Respiratory questionnaire. Tremor examination: signature, circle, square and spiral drawing.</p>	<p>Targeted anamnesis. Respiratory questionnaire. Tremor examination: signature, circle, square and spiral drawing. Biological monitoring (at the end of a five-working-day week): urine concentration of magnesium, expressed per gram creatinine.</p>	
3.1.14.	<b>MANGANESE AND ITS COMPOUNDS</b>	<b>MANGANESE AND ITS COMPOUNDS</b>	12
	<p>Targeted anamnesis. Q16 questionnaire. Tremor examination: signature, circle, square and spiral drawing. Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).</p>	<p>Targeted anamnesis. Q16 questionnaire. Tremor examination: signature, circle, square and spiral drawing. Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).</p>	
3.1.15.	<b>NICKEL AND ITS COMPOUNDS</b>	<b>NICKEL AND ITS COMPOUNDS</b>	12
	<p>Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Smell examination. Chest X-Ray (PA).</p>	<p>Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Smell examination. Chest X-Ray (PA). Biological monitoring (at the end of a five-working-day week): urine concentration of nickel, expressed per gram creatinine, and blood concentration of nickel.</p>	

	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
3.1.16.	<b>LEAD AND ITS INORGANIC COMPOUNDS</b>	<b>LEAD AND ITS INORGANIC COMPOUNDS</b>	12
	Targeted anamnesis. Q16 questionnaire. Determination of reticulocyte number, (total and direct) bilirubin, transaminasis (SGOT and SGPT), urea and creatinine in blood.	Targeted anamnesis. Q16 questionnaire. Determination of reticulocyte number, (total and direct) bilirubin, transaminasis (SGOT and SGPT), urea and creatinine in blood. Biological monitoring. Blood concentration of lead. Erythrocyte protoporphyrin concentration. Urine concentration of $\delta$ -aminolevulinic acid.	
3.1.17.	<b>ORGANIC COMPOUNDS OF LEAD</b>	<b>ORGANIC COMPOUNDS OF LEAD</b>	12
	Targeted anamnesis. Q16 questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood.	Targeted anamnesis. Q16 questionnaire. Determination of reticulocyte number, (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood.	
		Analysis of chromosomal aberrations and micronuclei.	
	<b>Note: Analysis of chromosomal aberrations and micronuclei every three years</b>		
3.1.18.	<b>PLATINUM AND ITS COMPOUNDS</b>	<b>PLATINUM AND ITS COMPOUNDS</b>	24
	Targeted anamnesis. Respiratory questionnaire. Detailed examination of upper respiratory tract mucous membrane and skin.	Targeted anamnesis. Respiratory questionnaire. Detailed examination of upper respiratory tract mucous membrane and skin.	
3.1.19.	<b>SELENIUM AND ITS COMPOUNDS</b>	<b>SELENIUM AND ITS COMPOUNDS</b>	12

	<p>Targeted anamnesis. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa in blood. Chest X-Ray (PA).</p>	<p>Targeted anamnesis. Respiratory questionnaire. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa in blood. Chest X-Ray (PA). Biological monitoring (at the end of a five-working-day week): urine concentration of selenium, expressed per gram creatinine, and blood concentration of selenium.</p>	
<b>Note: chest X-ray every three years after the five-year exposure.</b>			
3.1.20.	<b>THALLIUM AND ITS COMPOUNDS</b>	<b>THALLIUM AND ITS COMPOUNDS</b>	12
	<p>Targeted anamnesis. Respiratory questionnaire. Detailed examination of upper respiratory tract mucous membrane and skin. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood.</p>	<p>Targeted anamnesis. Respiratory questionnaire. Detailed examination of upper respiratory tract mucous membrane and skin. Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood. Biological monitoring (at the end of a five-working-day week): urine concentration of thallium, expressed per gram creatinine,</p>	
<b>Biological monitoring starting from 2010.</b>			
3.1.21.	<b>HARD METAL</b>	<b>HARD METAL</b>	12
	<p>Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).</p>	<p>Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).</p>	
<b>Note: chest X-ray every three years after the five-year exposure.</b>			
3.1.22.	<b>VANADIUM AND ITS COMPOUNDS</b>	<b>VANADIUM AND ITS COMPOUNDS</b>	12
	<p>Targeted anamnesis.</p>	<p>Targeted anamnesis.</p>	

	<p>Respiratory questionnaire.  Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa in blood.  Chest X-Ray (PA).</p>	<p>Respiratory questionnaire.  Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa in blood.  Chest X-Ray (PA).  Biological monitoring (at the end of a five-working-day week):  urine concentration of vanadium, expressed per gram creatinine, and blood concentration of vanadium.</p>	
<b>Note: chest X-ray every three years after the five-year exposure. Biological monitoring starting from 2010.</b>			
3.1.23.	<b>MERCURY AND ITS COMPOUNDS (EXCEPT FOR SHORT CHAIN CHEMICAL COMPOUNDS)</b>	<b>MERCURY AND ITS COMPOUNDS (EXCEPT FOR SHORT CHAIN CHEMICAL COMPOUNDS)</b>	12
	<p>Targeted anamnesis.  Q16 questionnaire.  Tremor examination: signature, circle, square and spiral drawing.  Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).  Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), urea and creatinine in blood.  Determination of urine concentration of albumins, <math>\beta</math>2-microglobulin (expressed per gram creatinine) and/or <math>\alpha</math>1-microglobulin (expressed per gram creatinine).</p>	<p>Targeted anamnesis.  Q16 questionnaire.  Tremor examination: signature, circle, square and spiral drawing.  Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).  Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), urea and creatinine in blood.  Determination of urine concentration of albumins, <math>\beta</math>2-microglobulin (expressed per gram creatinine) and/or <math>\alpha</math>1-microglobulin (expressed per gram creatinine).  Biological monitoring (at the end of a five-working-day week):  urine concentration of mercury, expressed per gram creatinine, and blood concentration of mercury.</p>	
3.1.24.	<b>SHORT CHAIN ORGANIC MERCURY COMPOUNDS</b>	<b>SHORT CHAIN ORGANIC MERCURY COMPOUNDS</b>	12

	<p>Targeted anamnesis. Q16 questionnaire. Tremor examination: signature, circle, square and spiral drawing. Vision functions testing: foria, fusion, color eyesight.</p>	<p>Targeted anamnesis. Q16 questionnaire. Tremor examination: signature, circle, square and spiral drawing. Vision functions testing: sharpness of near- and distance-vision, deep vision, foria, fusion, color eyesight.</p>	
	<p>Perimetry. Skin receptors examination (tactile, vibro, for pain). Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening). Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood.</p>	<p>Perimetry. Tonal liminar Audiometry. Pain, touch and temperature sensitivity examination of arms and legs. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening). Determination of (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood. Biological monitoring: blood concentration of mercury.</p>	
3.2.	<i>ORGANIC COMPOUNDS</i>	<i>ORGANIC COMPOUNDS</i>	
3.2.1.	<p><b>ALIPHATIC AND ALICYCLIC CARBOHYDRATES</b> (<i>n</i>-hexane, cyclohexane etc.)</p>	<p><b>ALIPHATIC AND ALICYCLIC CARBOHYDRATES</b> (<i>n</i>-hexane, cyclohexane etc.)</p>	12
	<p>Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).</p>	<p>Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Tonal liminar Audiometry. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).</p>	

	Determination of trombocyte number, (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood.	screening). Determination of trombocyte number, (total and direct) bilirubin, transaminasis (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood.	
		Biological monitoring: (on the last working day of the week at the shift end): <i>N</i> -hexane exposure: urine 2.5-hexandion. Cyclohexane exposure: urine cyclohexane.	
<b>Note: biological monitoring starting from 2010.</b>			
3.2.2.	<b>CYCLIC CARBOHYDRATES (AROMATIC CARBOHYDRATES)</b>	<b>CYCLIC CARBOHYDRATES (AROMATIC CARBOHYDRATES)</b>	12



	<p>Targeted anamnesis.  Q16 questionnaire.  Respiratory questionnaire.  Vision functions testing: color eyesight.  Pain, touch and temperature sensitivity examination of arms and legs.  Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).  Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood.</p>	<p>Targeted anamnesis.  Q16 questionnaire.  Respiratory questionnaire.  Vision functions testing: color eyesight.  Pain, touch and temperature sensitivity examination of arms and legs.  Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).  Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood.  Biological monitoring: (o on the last working day of the week at the shift end):  Benzene exposition: determination of benzene in urine, exhaled air or in the urine trans, trans-muconic acid;  Ethylbenzene exposition: determination of ethylbenzene in urine and/or mandelic acid in urine;  Toluene exposition: determination of toluene in blood or exhaled air;  Xylene exposition: determination of xylene in blood;  Styrene exposition: determination of styrene in blood or exhaled air or mandelic acid in urine;  Exposition to other cyclic carbohydrates: concentration of a compound or a specific metabolite in biological material.</p>	
<b>Note: biological monitoring starting from 2010.</b>			
3.2.3.	<b>AMINO AND NITRO COMPOUNDS OF CYCLIC CARBOHYDRATES, THEIR HOMOLOGUES AND DERIVATIVES</b>	<b>AMINO AND NITRO COMPOUNDS OF CYCLIC CARBOHYDRATES, THEIR HOMOLOGUES AND DERIVATIVES</b>	12

	<p>Targeted anamnesis.  Q16 questionnaire.  Respiratory questionnaire.  Vision functions testing: color eyesight.  Pain, touch and temperature sensitivity examination of arms and legs.  Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).  Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood.</p>	<p>Targeted anamnesis.  Q16 questionnaire.  Respiratory questionnaire.  Vision functions testing: color eyesight.  Pain, touch and temperature sensitivity examination of arms and legs.  Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).  Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood.  Biological monitoring: (on the last working day of the week at the shift end):  Aniline exposition: determination of urine p-aminophenol and methemoglobin;  Nitrobenzene exposition: determination of p-nitrophenol in urine and methemoglobin;  Expositin to other amino and nitro compounds of cyclic carbohydrates: concentration of a compound or a specific metabolite in biological material.</p>	
<b>Note: biological monitoring starting from 2010.</b>			
3.2.4.	<b>HALOGENOUS DERIVATIVES OF ALIPHATIC AND CYCLIC CARBOHYDRATES</b>	<b>HALOGENOUS DERIVATIVES OF ALIPHATIC AND CYCLIC CARBOHYDRATES</b>	12
	<p>Targeted anamnesis.  Q16 questionnaire.  Respiratory questionnaire.  Vision functions testing: color eyesight.  Pain, touch and temperature sensitivity examination of arms and legs.</p>	<p>Targeted anamnesis.  Q16 questionnaire.  Respiratory questionnaire.  Vision functions testing: color eyesight.  Pain, touch and temperature sensitivity examination of arms and legs.</p>	

		Tonal liminar Audiometry.	
	<p>Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).</p> <p>Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood.</p>	<p>Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening).</p> <p>Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood. Biological monitoring: (on the last working day of the week at the shift end):</p> <p>Trichlorethylene exposition: determination of trichloroacetic acid in urine, trichloroethanol in urine and total trichloro-compounds in urine or determination of trichloroethylene in urine and blood.</p> <p>Perchloroethylene exposition: determination of perchloroethylene in blood or exhaled air.</p> <p>Methyl chloroform exposition: determination of methyl chloroform in blood or trichloroethanol in urine.</p> <p>Dichloromethane exposition: determination of dichloromethane in blood or exhaled air, with carboxyhemoglobin determination.</p> <p>Exposition to other halogenous derivatives of aliphatic and cyclic carbohydrates: concentration of a compound or a specific metabolite in biological material.</p>	
<b>Note: biological monitoring starting from 2010, except for trichloroethylene.</b>			
3.2.5.	<b>VINYL CHLORIDE MONOMER</b>	<b>VINYL CHLORIDE MONOMER</b>	12
	<p>Targeted anamnesis.</p> <p>Respiratory questionnaire.</p> <p>Dynamic skin thermometric (Cold test).</p> <p>Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-</p>	<p>Targeted anamnesis.</p> <p>Respiratory questionnaire.</p> <p>Dynamic skin thermometric (Cold test).</p> <p>Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-</p>	

	glutamil transpeptidasa, urea and creatinine in blood.	glutamil transpeptidasa, urea and creatinine in blood.	
		Abdominal x-ray examination. Roentgenography of hands. Biological monitoring: determination of thiodiglycolic acid in urine, on the last working day of the week at the shift end):	
	<b>Note: Abdominal x-ray examination and roentgenography of hands every 5 years after the ten-year exposure.</b>		
3.2.6.	<b>ALCOHOLS, ESTERS, ETHERS, ALDEHYDES AND KETONES</b>	<b>АЛКОХОЛИ, ЕСТРИ, ЕТРИ, АЛДЕХИДИ И КЕТОНИ</b>	12
	Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Determination of the number of thrombocytes, (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamil transpeptidasa, urea and creatinine in blood.	Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Tonal laminar audiometry. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Determination of the number of thrombocytes, (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamil transpeptidasa, urea and creatinine in blood. Biological monitoring: determination of the primary substance metabolite, on the last working day of the week at the shift end.	
	<b>Note: biological monitoring starting from 2010.</b>		
3.2.7.	<b>CARBON DISULFIDE</b>	<b>CARBON DISULFIDE</b>	12
	Targeted anamnesis. Q16 questionnaire. Vision functions testing: color eyesight. Pain, touch and temperature sensitivity examination of arms and legs. Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening). Determination of (total and direct) bilirubins, transaminases	Targeted anamnesis. Q16 questionnaire. Vision functions testing: color eyesight. Pain, touch and temperature sensitivity examination of arms and legs. Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening). Determination of (total and direct) bilirubins, transaminases	

	(SGOT and SGPT), urea and creatinine in blood.	(SGOT and SGPT), urea and creatinine in blood. Biological monitoring: determination of 2-thiothiazolidin-4-carboxylic acid (TTCA) in urine on the last working day of the week at the shift end.	
3.2.8.	<b>PESTICIDES</b> (production, trade and use)	<b>PESTICIDES</b> (production, trade and use)	12
	<p>Targeted anamnesis. Q16 questionnaire. Respiratory questionnaire. Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening). Determination of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood. Determination of erythrocyte acetylcholinesterase (two values at least prior to acetylcholinesterase inhibiting compounds exposure, and provided the difference between the two values exceeds 20%, the analysis should be repeated).</p>	<p>Targeted anamnesis. Q16 questionnaire. Respiratory questionnaire. Psychological examination (examination of psycho-physiological abilities, personality characteristics and psycho-organic disorders screening). Determination of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, <math>\gamma</math>-glutamyl transpeptidasa, urea and creatinine in blood. Biological monitoring (at the end of the working day one has been exposed to pesticides): Exposition to the organophosphorous compounds-based pesticides: determination of urine alkyl phosphates or erythrocyte acetylcholinesterase; Exposition to carbamate-based pesticides: determination of erythrocyte acetylcholinesterase or determination of the specific metabolite in urine; Exposition to pyrethroids: determination of urine pyrethroids, alternatively 3-phenoxy benzene acid and 4-xydroxy-3-phenoxy benzene acid in urine; Lindane exposition: determination of blood lindane; Parathion exposition: urine p-nitrophenol; Dinitro-ortho-cresol exposition: determination of blood dinitro-ortho-cresol; Exposition to other pesticides: concentration of an active compound or a specific metabolite in biological material.</p>	

	<b>Note: Biological monitoring of exposition to other pesticides, except to organophosphates and carbamates, starting from 2010.</b>		
3.2.9.	<b>AMIDES, NN-DIMETHYLFORMAMIDE</b>	<b>AMIDES, NN-DIMETHYLFORMAMIDE</b>	12
	Targeted anamnesis. Respiratory questionnaire.	Targeted anamnesis. Respiratory questionnaire.	
	Determination of blood concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine. Chest X-Ray (PA).	Determination of blood concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine. Chest X-Ray (PA). Biological monitoring (on the last working day of the week at the shift end): determination of NN-dimethylformamide in urine or blood.	
	<b>Note: chest X-ray every three years after the five-year exposure. Biological monitoring starting from 2010.</b>		
3.2.10.	<b>ARTIFICIAL RESINS AND PLASTIC MASSES</b> (production, processing, use)	<b>ARTIFICIAL RESINS AND PLASTIC MASSES</b> (production, processing, use)	12
	Targeted anamnesis. Respiratory questionnaire. Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood.	Targeted anamnesis. Respiratory questionnaire. Determination of the number of reticulocytes, leukocyte formula thrombocytes, the concentration of (total and direct) bilirubins, transaminases (SGOT and SGPT), alkaline phosphatase, $\gamma$ -glutamyl transpeptidasa, urea and creatinine in blood. Biological monitoring (on the last working day of the week at the shift end): Exposition to phenolic resins: urine phenol determination. Exposition to cyanide resins: urine thiocyanate determination. Exposition to other resins and plastic masses: concentration of a compound or a specific metabolite in biological material.	
3.3.	<i>GASES</i>	<i>GASES</i>	
3.3.1.	<b>CYAN AND ITS COMPOUNDS</b>	<b>CYAN AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire.	Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire.	
	Tremor examination: signature, circle, square and spiral drawing.	Tremor examination: signature, circle, square and spiral drawing.	

	Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk).	Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Tonal laminar audiometry. Biological monitoring: urine thiocyanate concentration at the work time end.	
3.3.2.	<b>FLUORINE AND ITS COMPOUNDS</b>	<b>FLUORINE AND ITS COMPOUNDS</b>	12
	Targeted anamnesis. Respiratory questionnaire. Detailed examination of skin and mucous membranes.	Targeted anamnesis. Respiratory questionnaire. Detailed examination of skin and mucous membranes. Pelvis roentgenography. Biological monitoring (at the working week end): urine fluoride concentration expressed per gram creatinine.	
<b>Note: pelvis roentgenography every three years after the five-year exposure.</b>			
3.3.3.	<b>HALOGEN ELEMENTS AND THEIR COMPOUNDS (EXCEPT FLUORINE AND ITS COMPOUNDS)</b>	<b>HALOGEN ELEMENTS AND THEIR COMPOUNDS (EXCEPT FLUORINE AND ITS COMPOUNDS)</b>	12
	Targeted anamnesis. Respiratory questionnaire. Detailed examination of skin and mucous membranes.	Targeted anamnesis. Respiratory questionnaire. Detailed examination of skin and mucous membranes.	
3.3.4.	<b>PLAIN SUFFOCATORS (methane, ethane, carbon dioxide etc.)</b>	<b>PLAIN SUFFOCATORS (methane, ethane, carbon dioxide etc.)</b>	12
	Targeted anamnesis. Respiratory questionnaire. Detailed examination of the respiratory and cardiovascular systems.	Targeted anamnesis. Respiratory questionnaire. Detailed examination of the respiratory and cardiovascular systems.	
3.3.5.	<b>HYDROGEN SULFIDE</b>	<b>HYDROGEN SULFIDE</b>	12
	Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass	Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass	

	walk). Smell examination.	walk). Smell examination.	
3.3.6.	<b>CARBON MONOXIDE</b>	<b>CARBON MONOXIDE</b>	12
	Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Tremor examination: signature, circle, square and spiral drawing. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk).	Targeted anamnesis. Respiratory questionnaire. Q16 questionnaire. Tremor examination: signature, circle, square and spiral drawing. Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk). Biological monitoring: carbonilhemoglobine concentration at the work time end.	
3.4.	<i>OTHER SUBSTANCES</i>	<i>OTHER SUBSTANCES</i>	
3.4.1.	<b>GASSES, VAPORS, AEROSOLS WITH IRRITATING, BRONCHOCONSTRICTIVE AND ALLERGIC EFFECTS</b>	<b>GASSES, VAPORS, AEROSOLS WITH IRRITATING, BRONCHOCONSTRICTIVE AND ALLERGIC EFFECTS</b>	12
	Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Chest X-Ray (PA).	Targeted anamnesis. Respiratory questionnaire. Specific allergy questionnaire. Chest X-Ray (PA).	
	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
3.4.2.	<b>FIBROGENIC DUST</b> (free C and O <sub>2</sub> , asbestos atc.)	<b>FIBROGENIC DUST</b> (free C and O <sub>2</sub> , asbestos atc.)	12
	Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).	Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).	
	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
3.4.3.	<b>NON-FIBROGENIC DUST</b>	<b>NON-FIBROGENIC DUST</b>	12
	Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).	Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).	
	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
			12



3.4.4.	<b>ACIDS, BASES, THEIR ANHYDRIDES AND SALTS</b>	<b>ACIDS, BASES, THEIR ANHYDRIDES AND SALTS</b>	
	Targeted anamnesis. Respiratory questionnaire.	Targeted anamnesis. Respiratory questionnaire.	
	Detailed examination of skin, mucous membranes and teeth.	Detailed examination of skin, mucous membranes and teeth.	
3.4.5.	<b>ARTIFICIAL FERTILIZERS</b> (Production, trade and use)	<b>ARTIFICIAL FERTILIZERS</b> (Production, trade and use)	12
	Targeted anamnesis. Targeted examination of skin and visible mucous membranes. Respiratory questionnaire. Determination of (total and direct) bilirubins, transaminases (SGOT and SGPT), urea and creatinine in blood. Chest X-Ray (PA).	Targeted anamnesis. Targeted examination of skin and visible mucous membranes. Respiratory questionnaire. Determination of (total and direct) bilirubins, transaminases (SGOT and SGPT), urea and creatinine in blood. Chest X-Ray (PA).	
	<b>Note: chest X-ray every three years after the five-year exposure.</b>		
3.4.6.	<b>RADIOACTIVE SUBSTANCES AND SOURCES (EXCEPT IONIZING RADIATION) PROVED TO HAVE CANCEROGENIC INFLUENCE ON MEN (category A1 in the carcinogen list of the World Health Organization).</b>	<b>RADIOACTIVE SUBSTANCES AND SOURCES (EXCEPT IONIZING RADIATION) PROVED TO HAVE CANCEROGENIC INFLUENCE ON MEN (category A1 in the carcinogen list of the World Health Organization).</b>	12
	Targeted anamnesis.	Targeted anamnesis. Specific biomarkers of suitable carcinogen effects. Ultrasound examination of targeted organs and systems of organs.	
	<b>Note: Ultrasound examination of targeted organs and systems of organs, every 12 months after the ten-year exposition.</b>		
3.4.7.	<b>OTHER (UNMENTIONED) CHEMICAL SUBSTANCES, THAT IS, DANGEROUS AND INSUFFICIENTLY EXPLORED SUBSTANCES AND PRODUCTS</b>	<b>OTHER (UNMENTIONED) CHEMICAL SUBSTANCES, THAT IS, DANGEROUS AND INSUFFICIENTLY EXPLORED SUBSTANCES AND PRODUCTS</b>	12
	Targeted examinations and explorations concerning possible health consequences according to the current expert sources.	Targeted examinations and explorations concerning possible health consequences according to the current expert sources.	
<b>4.0.</b>	<b>BIOLOGICAL HARMFULNESS</b>	<b>BIOLOGICAL HARMFULNESS</b>	
4.1.	<b>TUBERCULOSIS BACILLUS EXPOSURE</b>	<b>TUBERCULOSIS BACILLUS EXPOSURE</b>	24

	Targeted anamnesis. Respiratory questionnaire. Tuberculin test. Chest X-Ray (PA).	Targeted anamnesis. Respiratory questionnaire. Chest X-Ray (PA).	
	<b>Note: chest X-ray every five years.</b>		
4.2.	<b>EXPOSURE TO HEPATITIS B AND/OR C VIRUSES</b>	<b>EXPOSURE TO HEPATITIS B AND/OR C VIRUSES</b>	24
	Targeted anamnesis. Specific biomarkers of the contact with a virus (for hepatitis B HBsAg and anti-HBc IgM and for hepatitis C anti-HCV). Determination of the number of thrombocytes, (total and direct) bilirubins, transaminases (SGOT and SGPT).	Targeted anamnesis. Specific biomarkers of the contact with a virus (for hepatitis B HBsAg and anti-HBc IgM and for hepatitis C anti-HCV). Determination of the number of thrombocytes, (total and direct) bilirubins, transaminases (SGOT and SGPT).	
4.3.	<b>EXPOSITION TO HIV VIRUS</b>	<b>EXPOSITION TO HIV VIRUS</b>	24
	Targeted anamnesis. Specific biomarkers of the contact with HIV virus. Determination of the number of thrombocytes, (total and direct) bilirubins, transaminases (SGOT and SGPT).	Targeted anamnesis. Specific biomarkers of the contacts with HIV virus. Determination of the number of thrombocytes, (total and direct) bilirubins, transaminases (SGOT and SGPT).	
4.4.	<b>EXPOSITION TO OTHER UNMENTIONED BIOLOGICAL HARMFULNESS</b>	<b>EXPOSITION TO OTHER UNMENTIONED BIOLOGICAL HARMFULNESS</b>	24
	Targeted anamnesis. Specific biomarkers of the contact with a biological agent. Determination of the number of thrombocytes, (total and direct) bilirubins, transaminases (SGOT and SGPT). Chest X-Ray (PA).	Targeted anamnesis. Specific biomarkers of the contact with a biological agent. Determination of the number of thrombocytes, (total and direct) bilirubins, transaminases (SGOT and SGPT). Chest X-Ray (PA).	
	<b>Note: chest X-ray every five years.</b>		
<b>5.0.</b>	<b>SPECIAL HARMFULNESS AND DANGERS</b>	<b>SPECIAL HARMFULNESS AND DANGERS</b>	
5.1.	<b>WORK AT HEIGHT</b>	<b>WORK AT HEIGHT</b>	12

	<p>Targeted anamnesis.  Vision functions testing: foria, fusion, color eyesight and perimetry.  Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk).  Psychological examination (examination of psycho-physiological abilities and personality characteristics).</p>	<p>Targeted anamnesis.  Functions testing: sharpness of near- and distance-vision, deep vision, foria, fusion, color eyesight and perimetry.  Balance testing (Romberg's test, sensitized Romberg's test, nystagmus examination, mimo demonstration test and compass walk).  Tonal liminar audiometry.  Psychological examination (examination of psycho-physiological abilities and personality characteristics).</p>	
<p><b>Note: Psychological examination every three years provided there are no other indications.</b></p>			

